VANCOUVER, Washington, Oct. 12, 2020 (GLOBE NEWSWIRE) — CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company“), a late-stage biotechnology company developing leronlimab (PRO
140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today its appointment of Chiral Pharma Corporation, a subsidiary of Philippine New Marketlink
Pharmaceutical Corporation (NMPC),